Lee, Ji-Hyun
Lee, Seung Hoon
Jeon, Chanhyeok
Han, Jinil
Kim, Sang-Hyon
Youn, Jeehee
Park, Ye-Soo
Kim, Tae-Jong
Kim, Jong-Seo
Jo, Sungsin http://orcid.org/0000-0003-3034-5029
Kim, Tae-Hwan http://orcid.org/0000-0002-3542-2276
Son, Chang-Nam
Funding for this research was provided by:
National Research Foundation of Korea (2021R1F1A1060970, 2019R1A2C2004214)
National Research Foundation of Korea (2021R1A6A1A03038899, 2020R1A2C1102386)
Korea Healthy Industry Development Institute (HI23C0661)
Daegu-Gyeongbuk Medical Innovation Foundation (B-A-H-21-02)
Article History
Received: 18 August 2023
Revised: 9 January 2024
Accepted: 5 February 2024
First Online: 29 February 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Hanyang University Hospital (2014–05-002) and approved by the Animals Ethics Screening Committee of Hanyang University (2021-0229A).
: Informed consent was obtained from all individual participants included in the study.
: Ji-Hyun Lee and Jinil Han are employed by Rheumarker Bio Inc. and Gencurix Inc., respectively. Chang-Nam Son is the chief executive officer (CEO) of Rheumarker Bio Inc. Other authors declare no conflicts of interest.